GRAND PHARM. GRP. HD-01
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells p… Read more
Market Cap & Net Worth: GRAND PHARM. GRP. HD-01 (MX6A)
GRAND PHARM. GRP. HD-01 (F:MX6A) has a market capitalization of $2.79 Billion (€2.71 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #7319 globally and #773 in its home market, demonstrating a -0.64% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GRAND PHARM. GRP. HD-01's stock price €0.78 by its total outstanding shares 3501809648 (3.50 Billion).
GRAND PHARM. GRP. HD-01 Market Cap History: 2021 to 2026
GRAND PHARM. GRP. HD-01's market capitalization history from 2021 to 2026. Data shows growth from $766.35 Million to $2.79 Billion (31.18% CAGR).
GRAND PHARM. GRP. HD-01 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GRAND PHARM. GRP. HD-01's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MX6A by Market Capitalization
Companies near GRAND PHARM. GRP. HD-01 in the global market cap rankings as of March 18, 2026.
Key companies related to GRAND PHARM. GRP. HD-01 by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #719 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #719 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
GRAND PHARM. GRP. HD-01 Historical Marketcap From 2021 to 2026
Between 2021 and today, GRAND PHARM. GRP. HD-01's market cap moved from $766.35 Million to $ 2.79 Billion, with a yearly change of 31.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €2.79 Billion | -14.84% |
| 2025 | €3.27 Billion | +62.50% |
| 2024 | €2.01 Billion | +107.48% |
| 2023 | €970.16 Million | +26.54% |
| 2022 | €766.71 Million | +0.05% |
| 2021 | €766.35 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of GRAND PHARM. GRP. HD-01 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.79 Billion USD |
| MoneyControl | $2.79 Billion USD |
| MarketWatch | $2.79 Billion USD |
| marketcap.company | $2.79 Billion USD |
| Reuters | $2.79 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.